课题基金 / 基金详情

Probing the Biochemical Mechanism of Amyloid Diseases

Probing the Biochemical Mechanism of Amyloid Diseases
探究淀粉样蛋白疾病的生化机制
批准号:
6925367
负责人:
JEFFERY W KELLY
金额:
$31.02万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-05-01 至 2006-09-29

项目摘要

项目成果

JEFFERY W KELLY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The long-term goal of this research is to understand the biochemical mechanism of human amyloid disease, such that novel mechanism-based small molecule and macromolecular therapeutic strategies can be developed. It is now possible to prepare and isolate hybrid transthyretin (TTR) tetramers of defined subunit composition, reflecting those found in heterozygous familial amyloid polyneuropathy patients. In aim 1, the kinetics and thermodynamics of denaturation and amyloidogenicity of the hybrid tetramers will be evaluated as a function of added binding partners and a variety of physiologically relevant conditions to better understand the mechanistic features of amyloidogenesis. The feasibility of a trans-suppression approach for therapeutic intervention will be evaluated, and in related studies, the idea that only certain hybrid tetramers will be amenable to fibril formation at a given denaturation stress level, will be tested. A folded monomeric version of TTR enables the kinetics and thermodynamics of the amyloidogenic tertiary structural changes to be studied independent of the quaternary structural changes. Several hypotheses will be tested, including the idea that amyloid fibrils derived from different sequences have unique quaternary structures. A structure-based design approach for discovering small molecule inhibitors of TTR amyloid fibril formation will be expanded in aim 2 to develop bivalent inhibitors, in an effort to test the amyloid hypothesis in vitro, in cell lines and in a murine animal model in vivo. The kinetics of binding and dissociation of the best structurally diverse inhibitors will be evaluated to better understand their efficacy. In aim 3, the mechanistic connection between amyloidogenesis and the neuropathology characterizing these diseases will be sought. Efficient intralysosomal amyloid formation is observed in a macrophage cell line fed L55P TTR, but not WT TTR. The decreased viability of the cells converting soluble L55P into amyloid allows the use of expression profiling and protein analysis to understand how it is that amyloidosis reprograms the cell for demise. The idea that a rare cell secreting amyloid fibrils (or a lysed amyloid laden cell) could infect cells in its vicinity leading to the rapid onset of disease will be explored also.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Probing the Proteinopathy Component of Light Chain Amyloidosis Pharmacologically
  • 批准号:
    10440457
  • 项目类别:
  • 资助金额:
    $44.38万
  • 财政年份:
    2021
  • 负责人:
    JEFFERY W KELLY
  • 依托单位:
Pharmacologic Lysosomal Flux Activators to Ameliorate Alzheimer's Disease and Related Dementias
  • 批准号:
    10281046
  • 项目类别:
  • 资助金额:
    $260.17万
  • 财政年份:
    2021
  • 负责人:
    JEFFERY W KELLY
  • 依托单位:
Probing the Proteinopathy Component of Light Chain Amyloidosis Pharmacologically
  • 批准号:
    10186362
  • 项目类别:
  • 资助金额:
    $44.38万
  • 财政年份:
    2021
  • 负责人:
    JEFFERY W KELLY
  • 依托单位:
Probing the Proteinopathy Component of Light Chain Amyloidosis Pharmacologically
  • 批准号:
    10625486
  • 项目类别:
  • 资助金额:
    $45.25万
  • 财政年份:
    2021
  • 负责人:
    JEFFERY W KELLY
  • 依托单位:
海外基金